Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.73), $0.09 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $55.24 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.